c-Src is frequently activated in NSCLC and transitional bladder cancer and administration of the Src inhibitor dasatinib abolished Src phosphorylation and sensitized lung and bladder cancer cells to cisplatin [29,30]. Here, SRC is linked to urinary bladder carcinoma.